Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis
Autor: | A. S. McIntyre, R. J. Nicholls, M. V. Madden |
---|---|
Rok vydání: | 1994 |
Předmět: |
medicine.medical_specialty
Physiology medicine.medical_treatment Placebo Gastroenterology Postoperative Complications Double-Blind Method Internal medicine Metronidazole medicine Humans Defecation Inflammation Mucous Membrane business.industry Proctocolectomy Proctocolectomy Restorative Pouchitis medicine.disease Crossover study Ulcerative colitis Diarrhea C-Reactive Protein Chronic Disease Colitis Ulcerative medicine.symptom business medicine.drug |
Zdroj: | Digestive diseases and sciences. 39(6) |
ISSN: | 0163-2116 |
Popis: | Metronidazole has been used to treat pouchitis, but there are no controlled data that show it is effective. Chronic unremitting pouchitis is a form of the disorder particularly difficult to manage. Diarrhea is the main symptom of pouchitis, which results from acute inflammation of the mucosa of an ileal reservoir. To test the hypothesis that metronidazole (400 mg thrice daily for seven days) is no better than placebo at reducing stool frequency in chronic unremitting pouchitis, a double-blind placebo-controlled crossover study has been performed. Thirteen patients who had undergone restorative proctocolectomy for ulcerative colitis were studied. The diagnosis of pouchitis was based on clinical, endoscopic, and histological criteria. At entry all patients had symptomatic pouchitis and were passing more than six stools/24 hr or had consistently bloody stools with at least four of six endoscopic criteria of mucosal inflammation. The median frequency of defecation decreased by 3 bowel action/24 hr (conservative 95% confidence intervals 0–4/24 hr) on metronidazole but increased by a median of 1/24 hr on placebo. The difference between the median number of bowel motions, when treatment with metronidazole was compared to placebo, was 4 motions/24 hr (P |
Databáze: | OpenAIRE |
Externí odkaz: |